Summary
A model of localised abscess formation was used to establish mixed infections caused byEscherichia coli andBacteroides fragilis. The β-lactamase producing, ticarcillin-resistant strainsE. coli E96 andB. fragilis VPI 8708 were used to produce one infection, and in another infection, a β-lactamase hyperproducing strainE. coli 41548 was combined with a ticarcillin-susceptible strain,B. fragilis B3. Treatment, at doses producing clinically achievable concentrations in mouse serum, began 1 h after inoculation, and continued three times daily for four days. Bacterial numbers in infected tissue were measured at intervals. Against both infections, ticarcillin was ineffective in preventing bacterial growth and abscess formation in all mice. Piperacillin prevented abscess formation in 60% of the mice infected withE. coli E96/B. fragilis VPI 8708, and in 40% of those in theE. coli 41548/B. fragilis B3 group. Therapy with ticarcillin/clavulanic acid or cefoxitin reduced the number of both organisms at the site of infection, and thus prevented abscess formation in 100% treated animals.
Zusammenfassung
Mischinfektionen mitEscherichia coli undBacteroides fragilis wurden mit einem Modell zur lokalisierten Abszeßbildung erzeugt. Bei einer Infektion wurden β-Laktamase bildende, ticarcillinresistente Stämme vonE. coli E96 undB. fragilis VPI 8708 und bei einer anderen Infektion derE. coli 41548- Stamm mit β-Laktamase-Überproduktion kombiniert mit einem ticarcillinempfindlichenB. fragilis B3-Stamm verwendet. Eine Stunde nach Inokulation wurde mit der Behandlung in Dosen begonnen, die im Serum der Maus in der klinischen Situation beim Menschen erreichbare Spiegel erzeugen; die Behandlung wurde dreimal täglich vier Tage lang fortgeführt. Im infizierten Gewebe wurden in bestimmten Abständen die Bakterienzahlen bestimmt. Ticarcillin konnte bei keiner der Infektionen das Wachstum der Bakterien und die Abszeßbildung in den Mäusen verhindern. Piperacillin verhinderte die Abszeßbildung bei 60% der Mäuse, die mitE. coli E96/B. fragilis VPI 8708 infiziert worden waren und bei 40% der mitE. coli 41548/B. fragilis B3 infizierten Tiere. Die Behandlung mit Ticarcillin/Clavulansäure oder Cefoxitin führte zu einer Reduktion der Keimzahlen beider Spezies am Ort der Infektion und verhütete damit die Abszeßbildung bei 100% der behandelten Tiere.
Similar content being viewed by others
References
Kaiser, A. B. Antimicrobial prophylaxis in surgery. N. Engl. J. Med. 315 (1986) 1129–1138.
McDonald, P. J., Karran, S. J. A comparison of intravenous cefoxitin and a combination of gentamicin and metronidazole as prophylaxis in colorectal surgery. Dis. Colon Rectum 26 (1983) 661–664.
Brown, J. J., Mutton, T. P., Wasilauskas, B. L., Myers, R. T., Meredith, J. H. Prospective, randomised, controlled trial of ticarcillin and cephalothin as prophylactic antibiotics for gastrointestinal operations. Am. J. Surg. 143 (1982) 343–348.
Sutherland, R., Beale, A. S., Boon, R. J., Griffin, K. E., Slocombe, B., Stokes, D. H., White, A. R. Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Am. J. Med. 79 (Suppl. B) (1985) 13–24.
Boon, R. J., Beale, A. S., Sutherland, R. Bactericidal effects of ticarcillin/clavulanic acid against β-lactamase producing bacteriain vivo. Antimicrob. Agents Chemother. 29 (1986) 838–844.
Jones, R. N., Wojeski, W. V. Single-dose surgical prophylaxis using ticarcillin/clavulanic acid (Timentin*): a prospective, randomised comparison with cefotaxime. Diagn. Microbiol. and Infect. Dis. 7 (1987) 219–223.
Tehan, S., Horobin, J., Gordonsmith, R., McLatchie, G. Ticarcillin plus clavulanic acid (Timentin*) — further UK trial results. Br. J. Clin. Pract. 42 (1988) 8–16.
Beale, A. S., Gisby, J., Sutherland, R. Efficacy of amoxycillin/clavulanic acid in experimentalBacteroides fragilis/Escherichia coli mixed infections. J. Antimicrob. Chemother. 21 (1988) 451–459.
Gisby, J., Beale, A. S. Comparative efficacies of amoxycillin/clavulanic acid and ampicillin/sulbactam against experimentalBacteroides fragilis/Escherichia coli mixed infections. Antimicrob. Agents Chemother. 25 (1984) 1830–1833.
Fuchs, P. C., Barry, A. L., Thornsberry, C., Jones, R. N. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob. Agents Chemother. 25 (1984) 392–394.
Scully, B. E., Chin, N-X., Neu, H. C. Pharmacology of ticarcillin combined with clavulanic acid in humans. J. Med. 79 (Suppl. 5B) (1985) 39–43.
Jackson, D., Tasker, T. C. G., Staniforth, D., Horton, R., Murray, A. T., Swaisland, A.: The bioavailability of parenteral Timentin* over the dose range 1.2 to 10.2gm. Proc. 13th I.C.C. Vienna.Spitzy, K. H., Karrer, K. (eds.) (1983) 55/43–46.
Mandell, G. In vitro microbiology and pharmacokinetics of piperacillin. Clin. Ther. 7 (Supplement A) (1985) 37–44.
Schrogie, J. J., Davies, R. O., Yeh, K. C., Rogers, D., Holmes, G. I., Skeggs, H.: Bioavailability and pharmacokinetics of cefoxitin sodium. J. Antimicrob. Chemother. 4 (Supplement B) (1978).
Burke, J. F. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 50 (1961) 161–168.
Walker, C. B., Nitzan, D., Wilkins, T. D. Chemotherapy of an experimentalBacteroides fragilis infection in mice. Antimicrob. Agents Chemother. 11 (1977) 435–440.
Vogelman, B., Gusmunsson, S., Leggett, J., Turnidge, J., Ebert, S. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158 (1988) 831–847.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beale, A.S., Gisby, J. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by escherichia coli and bacteroides fragilis. Infection 19, 101–105 (1991). https://doi.org/10.1007/BF01645577
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01645577